“Bioprinting of Hair: How Far We Proceeded and What Needs to be Done”

ABSTRACT

Alopecia is a common dermatologic disorder with psychological and quality‐of‐life impact. Current options such as PRP, topical agents, microneedling or dermarollers, drugs, and transplantation, often provide only partial or short‐term benefit and depend on existing follicles. 3D bioprinting is transforming regenerative trichology by positioning cells and “bioinks” to recreate hair‐bearing skin. Advances include biomimetic dermal papilla spheroids, follicle organoids in engineered dermis, and bioprinted skin equivalents with nascent HF‐like structures. Translation is limited by vascular and nerve integration and hair‐cycle control. These priorities will enable robust clinical regeneration. This review recapitulates the recent advances at the interface of hair‐follicle biology and 3D bioprinting, and delineates key bioengineering and cellular components underpinning folliculogenesis. Recent advancements have enabled the fabrication of biomimetic dermal papilla spheroids, the spatial integration of hair‐follicle organoids within engineered dermal matrices, and the fabrication of bioprinted skin equivalents containing nascent HF‐like structures, representing functional relevance for pharmacological evaluation and regenerative transplantation studies. Clinical translation of hair bioprinting remains impeded by the integration of functional vascular and neural networks, and recapitulating hair‐cycle dynamics. This review outlines strategic priorities required to move the field from experimental proof of concept to scalable, clinically relevant hair regeneration using bio‐prinking technology.

1. Introduction

Over the past 5 years, hair regenerative medicine has made significant strides from theoretical modeling to tangible proof‐of‐concepts representing the feasibility of fabricating organized hair‐follicle‐like structures via advanced bioprinting techniques (Motter Catarino et al. 2023; Kang et al. 2024). The current bioprinting achievement hinges on the successful recreation of the embryonic hair‐follicle germ (HFG) interaction between epithelial and mesenchymal compartments (Kang et al. 2023). In a landmark 2023 study, Nanmo et al. first demonstrated a bioprinting approach to generate hair‐follicle‐germ‐like microgels by placing adjacent mesenchymal and epithelial cell‐laden collagen droplets. The resulting constructs contracted in culture and, upon transplantation into mice, were able to regenerate hair follicles and shafts, validating the feasibility of these printed follicular germ constructs for de novo hair induction (Nanmo et al. 2023).

Expanding the field, Abaci and Rensselaer Polytechnic Institute [RPI] team reported a significant architectural breakthrough in 2023 by bioprinting organized follicular channels directly into engineered human‐derived skin tissue (Motter Catarino et al. 2023). These multicellular constructs, comprising keratinocytes, fibroblasts, and dermal papilla cells (DPCs), subsequently self‐assembled into organized, follicle‐like invaginations, offering a physiologically relevant in vitro model critical for both trichological studies and drug screening (Motter Catarino et al. 2023). In a parallel translational advancement, Kang et al. in 2024 demonstrated in situ bioprinting of adipose‐derived stem cells encapsulated in a bioactive extracellular matrix directly into a full‐thickness wound in an animal model, inducing follicle‐like downgrowths and nascent hair shaft formation in vivo (Kang et al. 2024). This intraoperative approach offers a clinically viable pathway for regenerating hair‐bearing skin, eliminating the need for prolonged ex vivo culture (Kang et al. 2024).

Subsequent research has broadened the scope of bioprinting by engineering biomimetic scaffolds that emulate the native follicular niche. Kang et al. (2023) fabricated a gelatin/alginate hydrogel [GAH] scaffold that supported DPCs spheroid assembly, enhanced proliferation (~1.2‐fold), and reinstated the expression of key trichogenic markers such as ALP, β‐catenin, and α‐SMA, culminating in the generation of early‐stage follicular structures in vivo (Kang et al. 2023). In a complementary approach, Catarino et al. (2023) incorporated DPC and human umbilical vein endothelial cell (HUVEC) spheroids into bioprinted human skin equivalents containing keratinocytes, fibroblasts, and melanocytes, successfully inducing follicle‐like invaginations within the dermal compartment (Motter Catarino et al. 2023). These multicellular constructs not only mimic the complexity of native follicular niches but also serve as preclinical platforms for promoting drugs and cosmetic formulations.

More recently, Ma et al. (2025) advanced the field by developing a prefabricated artificial skin construct through 3D bioprinting of a multicomponent hydrogel laden with epithelial and mesenchymal cell lineages, achieving simultaneous regeneration of both skin and hair follicles in an animal model (Ma et al. 2025). Their work underscores the critical role of recapitulating spatial heterogeneity and biochemical gradients within engineered constructs to enable complete and functional folliculogenesis. In parallel, recent reviews and conceptual frameworks have emphasized the integration of growth factors, such as FGF, VEGF, and TGF‐β and vascularization strategies to improve follicle viability, alignment, and maturation during bioprinting (Motter Catarino et al. 2023; Kang et al. 2024; Chu et al. 2025). Collectively, these developments underscore bioprinting's emergence as a transformative platform in regenerative trichology, complementing stem‐cell and growth‐factor‐based approaches while addressing challenges of scalability, reproducibility, and physiologic fidelity in engineered hair follicle constructs. Given the rapid progression in follicular bioprinting, Table 1 compiles landmark studies over past 5 years, highlighting their experimental approaches, bioink strategies, and principal outcomes.

Table 1.

Comparison of landmark studies in hari‐follicle bioprinting.

Study (year)	Bioprinting method	Cell type used	Bioink/Scaffold material	Main outcome	Reference
Nanmo et al. (2023)	Droplet‐based (inkjet)	DPCs + keratinocytes	Collagen microdroplets	Generated de novo hair shafts in vivo	Nanmo et al. (2023)
Catarino et al. (2023)	Extrusion printing	Keratinocytes, Fibroblasts, DPCs	Human skin ECM	Organized follicle‐like channels in skin equivalents	Motter Catarino et al. (2023)
Kang et al. (2024)	In situ bioprinting	ADSCs	ECM bioactive hydrogel	Induced hair‐like downgrowth's in wounds	Kang et al. (2024)
Kang et al. (2023)	Scaffold bioprinting	DPC spheroids	Gelatin/Alginate hydrogel	Enhanced proliferation and trichogenicity	Kang et al. (2023)
Ma et al. (2025)	Multicomponent 3D bioprinting	Epithelial + Mesenchymal cells	Multicomponent hydrogel	Regenerated skin + hair follicles	Ma et al. (2025)

2. Major Components and Requirement for Bioprinting of Hair

The successful regeneration of functional hair follicles via bioprinting necessitates a harmonized integration of multiple biological and engineering components. Broadly, these include (i) cellular constituents, (ii) bioinks/biomaterials, and (iii) precise bioprinting technologies, each playing a pivotal role in emulating the cellular complexity, biochemical environment, and structural hierarchy of native folliculogenesis.

2.1. Cellular Components

The foundation of hair follicle bioprinting relies on the intricate interplay between key cellular populations, most notably epithelial keratinocytes and DPCs. DPCs function as the mesenchymal signaling centre of the follicle, driving the initiation of hair germ development and coordinating subsequent growth cycles. However, expansion of DPCs in traditional 2D monolayers rapidly diminishes their trichogenic phenotype, necessitating alternative approaches such as 3D spheroid culture, co‐culture with endothelial cells, and transcriptional modulation to restore inductivity (Nanmo et al. 2023; Higgins et al. 2013; Abaci et al. 2017).

Epithelial keratinocytes, obtained from either native hair follicles or differentiated from induced pluripotent stem cell [iPSC]‐derived epithelial precursors, play a fundamental role in forming the outer sheath and hair shaft. Ensuring the appropriate stage of differentiation and lineage specification is essential for proper follicular morphogenesis (Yang et al. 2014). To replicate the native follicular microenvironment, recent approaches increasingly incorporate supportive cell types such as melanocytes, endothelial cells, fibroblasts, and neuronal or glial elements (Castro and Logarinho 2020). These accessory populations contribute distinct functional benefits‐endothelial cells facilitate pre‐vascularization, melanocyte restore pigmentation, and neuronal components enhance innervation and follicular cycling stability (Kageyama et al. 2021).

2.2. Bioinks and Biomaterials

The formulation of bioinks provides both the architectural framework and biochemical signaling environment essential for cell organization, survival, and follicular morphogenesis. Extracellular matrix (ECM)‐mimetic hydrogels, such as collagen type I/IV, gelatin‐methacrylate (GeIMA), alginate, fibrin, and hyaluronic acid blends, remain the most extensively used substrate for follicle bioprinting. These materials must achieve an optimal compromise between printability, mechanical stability, biodegradability, and biological permissiveness to facilitate follicular downgrowth, epithelial‐mesenchymal interactions, and tissue remodeling. Experimental studies have demonstrated that substrate stiffness, matrix porosity, and biochemical composition critically modulate DPC gene expression/β‐catenin signaling, and keratinocyte differentiation dynamics (Nanmo et al. 2023; Kageyama et al. 2021; Lv et al. 2024; Enshell‐Seijffers et al. 2010).

Modern formulations increasingly employ hybrid bioinks that combine ECM‐derived natural hydrogels with synthetic polymers (e.g., PEGDA, PCL) to achieve both bioactivity and structural integrity. The addition of growth factors and morphogens, including FGF, VEGF, BMP, Wnt, and Shh signaling activators, further enhances differentiation, morphogenesis, and alignment of follicular structures by recreating embryonic induction gradients (Chu et al. 2025). Controlled spatial delivery of these cues through patterned bioinks has been proposed to achieve more physiological follicular orientation and density (Lv et al. 2024; Gopinathan and Noh 2018).

Collectively, the transition from static hydrogels to adaptive, hybrid bioinks marks a critical advance toward recreating the complex biochemical and biophysical microenvironment required for functional hair follicle regeneration.

2.3. Bioprinting Technologies and Fabrication Strategies

The choice of bioprinting modality fundamentally determines spatial resolution, cell viability, and structural fidelity in engineered hair‐bearing skin constructs. Droplet‐based [inkjet] bioprinting provides precise microscale deposition of dermal papilla‐epithelial cell aggregates, successfully reproducing the spatial patterning characteristic of early hair germ morphogenesis (Nanmo et al. 2023; Kang et al. 2022). In comparison, extrusion‐based bioprinting enables the fabrication of stratified skin‐like architectures with embedded follicular channels, promoting seamless integration between dermal and epidermal compartments (Motter Catarino et al. 2023).

High‐resolution modalities such as laser‐assisted bioprinting (LAB) offer sub‐100 µM placement precision while maintaining excellent post‐printing cell viability, making them particularly advantageous for positioning follicular germ units and replicating the three‐dimensional geometry of native follicles (Murphy and Atala 2014; Abaci et al. 2018). Achieving spatial fidelity remains a core technical requisite‐accurate positioning of dermal papilla spheroids relative to the overlying epidermis typically requires ≤ 200 µM precision to ensure inductive signaling and proper downgrowth (Motter Catarino et al. 2023; Mali et al. 2018).

Recent advancements in multimaterial and coaxial bioprinting have expanded fabrication capabilities by enabling simultaneous deposition of multiple cell‐laden bioinks with distinct mechanical and biochemical properties. These systems can reproduce structural polarity and concentric layering, guide epithelial‐mesenchymal interactions, and facilitate the emergence of organized follicle‐like invaginations that better mimic in vivo morphology (Ma et al. 2025; Rossi et al. 2024; Sun et al. 2024). Additionally, bioprinting platforms using dynamic nozzle or coaxial extrusion technologies have been applied to generate pre‐vascularized skin constructs and complex skin appendages, representing a pivotal step toward translational follicle‐bearing skin regeneration (Yücer and Sarac 2025).

Collectively, these technological refinements are transforming follicular bioprinting from a rudimentary cell‐patterning process into a spatially programmed, multimaterial tissue‐engineering strategy capable of reproducing the hierarchical organization and inductive microarchitecture of the native hair follicle. A comprehensive summary of the cellular, biomaterial, and technological components involved in hair follicle bioprinting is illustrated in Figure 1.

Figure 1.

Integrated schematic of essential components and requirements for hair follicle bioprinting.

This diagram illustrates the three core pillars of hair follicle bioprinting: (i) Cellular components, including dermal papilla cells, epithelial keratinocytes, melanocytes, fibroblasts, endothelial and neural support; (ii) Bioinks and biomaterials, highlighting ECM‐derived hydrogels, hybrid matrices, and morphogen‐enriched formulations that support epithelial‐mesenchymal crosstalk; and (iii) Bioprinting technologies, including inkjet, extrusion, laser‐assisted, and multimaterial/coaxial modalities that enable precise spatial placement and hierarchical follicular architecture.

2.4. Signaling, Biophysical Cues, and Integration

The functional maturation of bioprinted hair follicles is governed not only by structural fidelity but also by the precise orchestration of signaling pathways and biomechanical gradients that emulate the morphogenetic environment of embryonic folliculogenesis. The localized and sustained presentation of morphogens, including Wnt, BMP, FGF, and Sonic hedgehog (Shh) pathways, within bioinks has been shown to direct follicular induction, axis orientation, and downgrowth, mirroring early developmental patterning events (Lv et al. 2024). Simultaneously, matrix stiffness, viscoelasticity, and microscale topographical features serve as mechanotransducive regulators, modulating epithelial‐mesenchymal crosstalk and influencing dermal papilla cell gene expression, keratinocyte differentiation, and overall follicular alignment (Fujiwara 2024).

Successful integration of bioprinted follicles with host tissue also requires the formation of functional vascular and neural interfaces, which are essential for metabolic support, neuroendocrine communication, and cyclical hair regeneration. Incorporation of angiogenic and neurotrophic cues, alongside co‐culture with endothelial and neuronal populations, has significantly enhanced vascularization, innervation, and long‐term graft survival in engineered follicular constructs (Xia et al. 2024).

To overcome diffusion limitations in larger constructs, advanced vascularization strategies have emerged, including co‐printing of endothelial networks, embedding angiogenic factor gradients, and fabrication pre‐vascualrized microchannels within hybrid bioinks. These innovations markedly improve perfusion efficiency, inosculation kinetics, and post‐implantation follicle survival, offering a scalable pathway toward clinically viable, hair‐bearing skin equivalents (Shukla et al. 2024). Collectively, these integrated biochemical and biophysical approaches are redefining follicular bioprinting as a dynamic, systems‐level tissue engineering platform capable of achieving both structural and functional regeneration.

2.5. Manufacturing and Translational Considerations

Bridging the gap between experimental follicular constructs and clinically applicable hair regeneration therapies necessitates the establishment of standardized manufacturing and regulatory frameworks compliant with Good Manufacturing Practice (GMP) guidelines. Critical requirements include defined and traceable cell sourcing protocols, reproducible spheroid or organoid generation workflows, and validated potency assays capable of quantifying the hair‐inductive capacity of dermal papilla cells. Additionally, quality control parameters‐encompassing construct morphology, cellular viability, sterility, and functional uniformity‐must be rigorously characterized to ensure reproducibility and safety across production batches (Shimizu et al. 2022; Zhang et al. 2024; Betriu et al. 2020).

Recent advances in automated bioprinting and robotic microtissue fabrication platforms have enabled the scalable production of follicular spheroids or “hair germ seeds” with consistent geometry and cell composition, thereby improving translational reproducibility. Integration of closed‐loop bioprinting systems, in‐line imaging, and machine learning‐based process monitoring is further enhancing real‐time control over construct architecture and deposition accuracy, aligning laboratory protocols with preclinical manufacturing standards (Nanmo et al. 2023).

Collectively, the synergy between optimized cellular bio assemblies, ECM‐inspired and regulatory‐compliant bioinks, high‐precision bioprinting modalities, and scalable automation defines the translational pathway required to move bioprinted hair follicle systems from bench‐scale feasibility to clinically deployable regenerative products. To provide a structured overview of the essential elements required for successful hair follicle biorprinting, Table 2 outlines the major biomaterials, technological, and translational components involved, along with their representative approaches and persistent challenges.

Table 2.

Key components and design frameworks for hair follicle bioprinting.

Component	Key features/Requirements	Approaches	Challenges
Cellular Components	Coordinated epithelial‐mesenchymal signaling with inductive DPCs	DPCs aggregate/spheroids, iPSC‐derived keratinocytes	Decline in DPC inductivity; variability between donors
Bioinks and Matrix System	Biomimetic extracellular matrix (ECM) signals with mechanical support	Collagen based hydrogels, GeIMA alginate blends, fibrin, PEGDA	Difficult balance between structural printability and bifunctionality
Bioprinting Platform	Spatial precision with cell viability	Inkjet/droplet methods, extrusion system, laser‐assisted and coaxial modalities.	Achieving orientation and follicle density control
Signaling and Biophysical Inputs	Localized morphogen cues (Wnt, BMP, FGF, Shh) and tunable matrix mechanics	Patterned morphogen delivery, topography	Achieving synchronized folliculogenesis
Manufacturing and Clinical Translation	GMP compliant workflows, automation, reproducibility	Robotic spheroid fabrication, AI enhanced quality monitoring	Regulatory gaps, hurdles in scaling for clinical use

2.6. Advances in Hair Follicle Bioprinting and Its Use in Trichology

Recent developments in three‐dimensional (3D) bioprinting have significantly advanced the application of hair follicle (HF) models in regenerative medicine and experimental trichology. Bioprinted skin constructs containing follicular units provide a more physiologically relevant microenvironment compared to conventional two‐dimensional assays, effectively recapitulating epithelial‐mesenchymal crosstalk crucial for follicle morphogenesis and cycling (Ma et al. 2025; Zhang et al. 2023). These composite systems now serve as functional in vitro platforms for screening hair‐growth modulators, cosmetic formulations, and potential toxic agents under near‐physiological conditions. Catarino et al. [2023] demonstrated reproducible bioprinted arrays of dermal papilla‐epithelial spheroids within human skin equivalents, generating uniform follicle‐like invaginations suitable for medium‐to high‐throughput testing (Motter Catarino et al. 2023). Such platforms are increasingly valued for their predictive accuracy in evaluating drug efficacy and safety before clinical translation.

Parallel progress in automated spheroid fabrication and robotic micro dispensing technologies has improved the reproducibility and scalability of HF germ production. These systems enable the generation of uniformly sized dermal papilla (DP) spheroids with preserved trichogenic potential, while robotic placement ensures sub‐200 µM precision relative to epidermal layers (Motter Catarino et al. 2023). Such innovations mark a crucial transition from manual, proof‐of‐concept fabrication to standardized manufacturing workflows. Recent reports describe automated bioprinting pipelines capable of producing hundreds of organized HF germs per batch with consistent morphology and inductive properties, representing a milestone in the path with consistent morphology and inductive properties, representing a milestone in the path toward clinical manufacturing (Nanmo et al. 2023; Sugiyama et al. 2024).

Beyond experimental use, HF‐integrated bioprinted skin has shown promise for wound healing and reconstructive surgery. Preclinical studies reveal that follicle‐bearing grafts not only restore epidermal architecture but also enhance pigmentation, vascularization, and mechanical elasticity compared to follicle‐free counterparts (Kang et al. 2024). These findings suggest a rational translational route, beginning with reconstructive and burn therapies before progressing to elective hair restoration applications, consistent with current ethical and regulatory frameworks.

Moreover, the precision and modularity of modern bioprinting platforms have opened new avenues in mechanistic trichology. Controlled co‐culture and spatial positioning of DPC spheroids, keratinocytes, and accessory cells allow systemic dissection of signaling cascades governing folliculogenesis, particularly Wnt/β‐catenin, BMP, FGF, and Sonic hedgehog [Shh] pathways (Jeong et al. 2024; Vatanashevanopakorn and Sartyoungkul 2023). These tunable, reproducible systems enable researchers to manipulate biochemical gradients, extracellular matrix stiffness, and morphogen localization to study how spatial and temporal cues regulate HF induction, spacing, and cycling. Consequently, 3D‐bioprinted follicle models now serve as both experimental platforms for basic hair biology and translational tools driving next‐generation regenerative therapies in trichology (Motter Catarino et al. 2023).

2.7. Technical Barriers

Despite remarkable advances in follicular bioprinting, several formidable technical and biological challenges continue to hinder the translation of these systems into clinically, scalable therapies. These obstacles span cellular, material, and manufacturing domains, collectively defining the “translational gap” between experimental prototypes and regenerative hair restoration products. An overview of the major scientific and engineering constraints is illustrated in the Figure 2.

Figure 2.

Technical barriers in hair follicle bioprinting.

Infographic summarizing major obstacles limiting the maturation and clinical translation if engineered hair follicles, including: loss of dermal papilla inductivity, challenges in achieving physiological follicle orientation and density, insufficient vascularization and perfusion, incomplete cycling and pigmentation competence, and regulatory constraints associated with complex multicellular engineered tissues.

2.8. Loss of Dermal Papilla (DP) Inductivity

The loss of DP inductivity during in vitro expansion remains the most persistent bottleneck in hair follicle bioprinting. Human DP cells rapidly lose their trichogenic gene expression profile and capacity to induce folliculogenesis after repeated passages in 2D culture (Higgins et al. 2013; Driskell et al. 2011). While three‐dimensional spheroid aggregation and co‐culture with endothelial or keratinocyte populations partially restore inductivity, these methods often lack scalability and standardization. Moreover, inter‐donor variability and undefined serum‐based media contribute to inconsistent outcomes. Emerging strategies‐including transcriptional reprogramming using Wnt/β‐catenin activators, hypoxic preconditioning, and encapsulation within biomimetic hydrogels‐have demonstrated partial restoration of DP function (Zhang et al. 2024), yet a reproducible, GMP‐compliant method to mass‐produce inductive human DP spheroids remains elusive. This biological instability continues to represent the single largest barrier to reliable follicle formation in bioprinted constructs.

2.9. Scale, Density, and Orientation Control

Clinical hair restoration requires high follicular density (40–100 follicles/cm²) and consistent angulation relative to the scalp surface to mimic natural hair orientation. Current bioprinting technologies face a trade‐off between spatial resolution, deposition speed, and cell viability. Although droplet‐and laser‐assisted platforms can achieve sub‐100 µM placement accuracy (Murphy and Atala 2014), scaling this precision to centimeter‐scale constructs while maintaining follicular organization remains technically demanding. Furthermore, coordinating the polarity between dermal and epithelial compartments to achieve oriented follicle downgrowth is yet unresolved. Advanced strategies such as coaxial bioprinting, multimaterial layering, and gradient‐guided printing have improved alignment (Ma et al. 2025), but throughput and uniformity remain factors for clinical translation.

2.10. Vascularization and Inosculation Speed

Another critical limitation is the lack of rapid vascular integration in bioprinted skin‐hair composites. Dense, cell‐laden constructs rely on sufficient perfusion for nutrient and oxygen exchange; without functional vasculature, central necrosis and follicle regression occur shortly after implantation (Liu et al. 2025). Approaches such as co‐printing endothelial cell networks, incorporating angiogenic factors (VEGF, PDGF‐B), and designing pre‐formed microchannels have shown promise in accelerating inosculation with host vasculature (Liu et al. 2025). However, long‐term survival still depends on achieving a balance between construct thickness, vascular density, and host integration speed. The development of bioprinted vascularized skin matrices that support both follicle survival and synchronized hair cycling remains a high‐priority goal for translation.

2.11. Pigmentation, Cycling Control, and Innervation

Reproducing the full functionality of natural hair follicles also requires the incorporation of melanocytes, neural elements, and cycling signaling regulation. Stable pigmentation demands not only melanocyte integration but also paracrine signaling from DP and keratinocytes to support melanin synthesis and transfer. Similarly, maintaining hair cycle control [anagen‐catagen‐telogen transitions] in vitro or after transplantation remains unsolved, largely due to incomplete recreation of the follicular stem cell niche. Innervation essential for tactile sensation and neurosensory regulation of cycling has yet to be effectively recapitulated in any bioprinted follicle system. Emerging research using neurotrophic factor gradients and co‐printing of glial and sensory neuron precursors offers potential, but these remain early‐stage experimental efforts (Lv et al. 2024; Coutant et al. 2024).

2.12. Potency Assays, Regulatory, and Manufacturing Challenges

Finally, standardization and regulatory validation constitute major non‐technical barriers. There is currently no universally accepted in vitro potency assay that reliably predicts the in vivo hair‐inducing capacity of a bioprinted construct (Shimizu et al. 2022; Hamida et al. 2024). Furthermore, defining release criteria, shelf stability, and long‐term safety for multicellular, matrix‐embedded products remains challenging under GMP frameworks. Automated bioprinting systems and closed‐loop monitoring have improved reproducibility, yet the absence of harmonized regulatory guidelines for cell‐laden printed tissues complicates clinical translation. Establishing validated potency markers, scalable GMP workflows, and early regulatory engagement will be pivotal for progressing from preclinical feasibility to human trials (Mladenovska et al. 2023).

2.13. Unmet Needs and Future Directions

Although remarkable progress has been achieved in the field of follicular bioprinting, several key scientific, engineering, and translational gaps must be addressed before this technology can deliver clinically viable hair regeneration. The next phase of development must integrate insights from stem cell biology, material science, and regulatory bioengineering to bridge the divide between laboratory innovation and clinical applicability.

2.14. Enhancing DP Inductivity and Cellular Maturity

A critical unmet need remains the stabilization and enhancement of human DP cell inductivity during culture and printing. Even the most advanced 3D culture systems exhibit variable trichogenic performance due to donor heterogeneity and loss of inductive gene expression over serial passages (Zhang et al. 2024). Future work must prioritize genomic and epigenetic reprogramming approaches, such as transient activation of Wnt/β‐catenin or Lef1 pathways, and develop defined, serum‐free media that support long‐term inductive phenotypes. The generation of universal, allogeneic DP cell lines through iPSC technology, gene editing, or immortalization strategies could further ensure consistency and scalability for clinical applications. Additionally, understanding the mechanobiological cues that preserve DP signature gene networks under dynamic printing conditions remains and an essential direction for investigation (Zhang et al. 2024).

2.15. Integration of Advanced Bioinks and Microenvironmental Control

Despite progress in hydrogel formulation, next‐generation bioinks capable of active signaling and remodeling are still needed. Most current ECM‐mimetic hydrogels are compositionally static and lack the ability to mimic the spatiotemporal stiffness and biochemical gradients characteristic of native follicular niches (Lv et al. 2024; Nam et al. 2025). Future bioinks should incorporate stimuli‐responsive polymers that can stiffen, soften, or release morphogens in response to local cell behavior. Incorporating micro‐ or nano‐topographical patterning could also improve epithelial‐mesenchymal alignment during follicle downgrowth. Parallel advances in multi‐material and gradient printing platforms‐such as coaxial extrusion or volumetric photopolymerization may enable the controlled deposition of different bioinks to replicate the dermal‐epidermal polarity and curvature seen in natural follicles (Ma et al. 2025).

2.16. Vascularization, Innervation, and Functional Integration

To achieve functional skin‐hair regeneration, vascular and neural integration must be optimized. Current approaches employing endothelial co‐printing or angiogenic growth factors only partially restore perfusion, with delayed inosculation leading to follicular atrophy or fibrosis (Liu et al. 2025). Future constructs should integrate hierarchical vascular channels and pre‐patterned neural scaffolds to accelerate host‐graft integration. The use of microfluidic perfusion bioreactors and bioelectronic stimulation could further enhance tissue maturation and synchronization of follicular cycling post‐transplantation. Moreover, leveraging organ‐on‐a‐chip models that incorporate perfusable vasculature and innervated follicle units could serve as test beds for refining vascular‐neural co‐development before in vivo deployment (Jeong et al. 2024).

2.17. Achieving Pigmentation and Hair Cycle Regulation

Stable pigmentation and cyclical regeneration remain unresolved challenges. The incorporation of melanocytes into printed constructs has produced partially pigmented hair shafts in animal models; however, achieving coordinated melanin synthesis and transfer within human‐scale constructs is still inconsistent (Motter Catarino et al. 2023). Additionally, establishing a self‐sustaining hair‐cycle ‐with defined anagen, catagen, and telogen transitions‐requires the recreation of the follicular stem‐cell niche and its dynamic paracrine environment. Future systems could use synthetic morphogen gradients or optogenetic control to periodically activate growth‐related pathways (e.g., Wnt and Shh), enabling engineered cycling behavior. This will also demand longitudinal in vivo studies to confirm that regenerated follicles maintain stable function over multiple cycles (Chu et al. 2025; Lv et al. 2024).

2.18. Development of Predictive Potency Assays and Regulatory Standards

A major translational gap lies in the absence of validated potency assays capable of predicting in vivo folliculogenic performance. Current evaluation methods rely on murine transplantation models, which are costly, time‐consuming, and poorly standardized (Xu et al. 2022). The field urgently requires quantitative molecular or imaging‐based readouts‐such as DP‐specific gene expression panels, spheroid morphology indices, or label‐free Raman spectroscopy signatures that correlate with inductive outcomes. Regulatory agencies are also beginning to define frameworks for complex bioprinted constructs, but harmonization remains incomplete. Further regulatory convergence between cell‐therapy, tissue‐engineered product, and combination device categories will be essential to streamline clinical approval pathways. Developing GMP‐compatible workflows, automated monitoring systems, and standardized quality‐control checkpoints will ensure reproducibility and patient safety (Sekar et al. 2021).

2.19. Concluding Remarks and Pathway Toward Clinical Translation

Realistically, early clinical applications of hair bioprinting are more likely to emerge in reconstructive medicine rather than elective cosmetic restoration. Follicle‐bearing skin grafts could restore both function and esthetics following trauma, burns, or surgical excision, addressing critical unmet needs that conventional therapies cannot fully satisfy (Bellani et al. 2025). Preclinical studies using growth‐factor‐based formulations such as QR678 and QR678 Neo have demonstrated low cytotoxicity, favorable biocompatibility, and the ability to enhance follicular activity in animal models, supporting the relevance of soluble regenerative cues in early translational frameworks (Kapoor et al. 2020). These initial translational studies will provide essential insights into safety, integration, and immunogenicity, forming the foundation for eventual applications in conditions such as androgenetic alopecia. Furthermore, a multinational Phase‐IV clinical study showed that intradermal QR678 Neo significantly improved hair density, thickness, and patient‐reported outcomes with a strong safety profile, illustrating how adjunctive regenerative therapies could complement or bridge the transition toward more complex bioprinted follicular constructs (Clinic et al. 2022).

Comparisons with current minimally invasive treatments, including intradermal growth factor injections and topical applications, highlight the potential for bioprinted constructs to overcome limitations in efficacy, uniformity, and scalability seen in conventional interventions (Shome et al. 2022; Kumar et al. 2024). Parallel collaborations between academia, industry, and regulatory authorities will be crucial to establish standardized benchmarks, develop biobanks for dermal papilla and epithelial cells, and create open‐access datasets to ensure reproducibility and accelerate translation. Ultimately, the convergence of bioprinting, stem cell biology, and regenerative dermatology will define a roadmap for moving follicular bioprinting from experimental feasibility to a clinically transformative technology.

Author Contributions

Conceptualization: Dr. Mamata Mishra and Dr. Debraj Shome. Manuscript writing and editing: Dr. Mamata Mishra and Dr. Khushbu Kumari. Reviewing and critical revision of the manuscript: Dr. Mamata Mishra, Dr. Rinky Kapoor, Dr. Sunil Keswani and Dr. Debraj Shome. All authors have unanimously read, reviewed, and approved the final version of the manuscript for submission.

Funding

The authors have nothing to report.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.